A case of pediatric acute myeloid leukemia with t(11;16)(q23;q24) leading to a novel KMT2A-USP10 fusion gene.
Elena ZerkalenkovaSvetlana LebedevaAnna KazakovaPavel BaryshevClaus MeyerRolf MarschalekGalina NovichkovaMichael MaschanAleksey MaschanYulia OlshanskayaPublished in: Genes, chromosomes & cancer (2018)
We present a leukemia case that exhibits a chromosomal translocation t(11;16)(q23;q23), which results in the expression of a novel KMT2A fusion gene. This novel fusion, KMT2A-USP10, was found in a relapse of acute myeloid leukaemia M5a. USP10 belongs to a protein family that deubiquitinates a distinct set of target proteins, and thus, increases the steady state protein levels of its target subproteome. One of the USP10 targets is TP53. Wildtype TP53 is usually rescued from proteasomal degradation by USP10. As most KMT2A leukemias display wildtype p53 alleles, one might argue that the disruption of an USP10 allele can be classified as a pro-oncogenic event.
Keyphrases
- acute myeloid leukemia
- copy number
- bone marrow
- poor prognosis
- genome wide
- binding protein
- protein protein
- liver failure
- dendritic cells
- transcription factor
- amino acid
- intensive care unit
- respiratory failure
- genome wide identification
- young adults
- allogeneic hematopoietic stem cell transplantation
- small molecule
- long non coding rna
- drug induced